Redefining Cellular Therapy: The Breakthrough of RB-1355

In the evolving landscape of cancer immunotherapy, lymphodepleting chemotherapy has long been considered a necessary prelude to treatment. For traditional cellular therapies like chimeric antigen receptor T-cell and NK-cell infusions, this "preconditioning" is vital to clear a biological path, removing endogenous cells that would otherwise outcompete the therapy for essential survival signals.

However, recent findings from the RB-1355 trials are challenging this paradigm. RB-1355 has demonstrated a remarkable ability to engraft and expand effectively in non-preconditioned hosts, marking a significant shift in how we approach myeloid-based interventions.

In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and presenting author of the trial, explained the mechanism of action of RB-1355 and what it could offer to patients with B-cell and T-cell lymphomas.